You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
鉅子生物(02367.HK):超額配股權已獲悉數行使、涉及339.12萬股
格隆匯 11-27 20:17

格隆匯11月27日丨鉅子生物(02367.HK)公佈,於2022年11月25日收市後,聯席全球協調人(為其本身及代表國際包銷商)已悉數行使超額配股權,涉及合共339.12萬股股份(“超額配發股份”),佔任何超額配股權獲行使前根據全球發售初步可供認購的發售股份總數的約15%。

根據Goldman Sachs International(高盛(亞洲)有限責任公司的聯屬人士)與Juzi Holding Co.,Ltd訂立的借股協議,Goldman Sachs International已從Juzi Holding Co.,Ltd借入合共339.12萬股股份以補足國際發售的超額分配。超額配發股份將用於促進向Juzi Holding Co.,Ltd歸還借入的股份。

公司將以每股股份24.30港元(即國際發售價)(不包括1.0%經紀佣金、0.0027%證監會交易徵費、0.005%香港聯交所交易費及0.00015%會財局交易徵費)配發及發行超額配發股份。

香港聯交所上市委員會已批准超額配發股份的上市及買賣。超額配發股份將於2022年11月30日上午九時正開始在香港聯交所主板上市及買賣。

經扣除公司就行使超額配股權應付的發售費用後,公司將就發行超額配發股份收取額外所得款項淨額約7790萬港元。公司擬將額外所得款項淨額用於招股章程“未來計劃及所得款項用途”一節所載相同用途。

公司進一步宣佈,有關全球發售的穩定價格期間於2022年11月27日(即遞交香港公開發售申請截止日期後第30日)結束。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account